Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Assets: 2010-2025

Historic Assets for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $1.4 billion.

  • Ani Pharmaceuticals' Assets rose 9.38% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 9.38%. This contributed to the annual value of $1.3 billion for FY2024, which is 41.94% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Assets stood at $1.4 billion for Q3 2025, which was up 4.85% from $1.3 billion recorded in Q2 2025.
  • Ani Pharmaceuticals' Assets' 5-year high stood at $1.4 billion during Q3 2025, with a 5-year trough of $463.8 million in Q1 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Assets value was $920.8 million (recorded in 2024), while the average stood at $1.1 billion.
  • The largest annual percentage gain for Ani Pharmaceuticals' Assets in the last 5 years was 67.31% (2021), contrasted with its biggest fall of 3.81% (2021).
  • Ani Pharmaceuticals' Assets (Quarterly) stood at $771.6 million in 2021, then dropped by 1.49% to $760.1 million in 2022, then rose by 18.99% to $904.4 million in 2023, then spiked by 41.94% to $1.3 billion in 2024, then increased by 9.38% to $1.4 billion in 2025.
  • Its Assets stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.